Germline POT1 mutations have previously been identified in various cancers: acute myeloid leukaemia (AML) [13], chronic lymphocytic leukaemia (CLL) [14], chronic myelomonocytic leukaemia, hairy cell leukaemia, myeloproliferative neoplasms (MPN), myelodysplastic syndrome [15], Hodgkin lymphoma [16], angiosarcoma, breast sarcoma [17], colorectal cancer [18], gliomas [19], melanoma ([11], [20]), osteosarcoma [21], and thyroid cancer [22]. This evidence concerns the gene POT1 and melanoma.